Answer
Apr 22, 2026 - 02:15 PM
The boxed warning for INGREZZA (valbenazine) concerns an increased risk of depression, suicidal thoughts, and suicidal behavior in patients with Huntington's disease.
INGREZZA is used to treat tardive dyskinesia and chorea associated with Huntington's disease. The boxed warning specifically addresses patients with Huntington's disease, who may already have an increased risk of depression and suicidal behavior.
Important precautions include:
-
Depression: INGREZZA may cause new or worsening depression in patients with Huntington's disease.
-
Suicidal thoughts or behavior: Patients should be monitored for changes in mood, behavior, or suicidal thinking.
-
History of mental health conditions: Extra caution is needed for patients with a history of depression, suicidal thoughts, or suicide attempts.
-
Regular monitoring: Healthcare providers should assess mood and behavior throughout treatment.
Seek immediate medical attention if suicidal thoughts, severe depression, or sudden concerning behavioral changes develop.
Important: This boxed warning specifically applies to patients with Huntington's disease and does not mean that everyone taking INGREZZA for tardive dyskinesia will experience these effects. However, all patients should discuss potential risks and side effects with their healthcare provider.
